β-Blockers for the Treatment of Misophonia and Misokinesia. Webb, J. Clinical neuropharmacology, 45(1):13–14, February, 2022. Number: 1 Place: United States
doi  abstract   bibtex   
Misophonia is an adverse physical and emotional reaction to certain repetitive trigger sounds, usually generated by other people. Misokinesia refers to visual triggers that are sometimes (but not always) related to trigger sounds. Despite how common and disabling these conditions can be, medication treatment of misophonia and misokinesia is largely unexplored. We present the first case of using a β-blocker (propranolol) to successfully treat a patient experiencing misophonia and misokinesia. A moderate dose (60 mg) of propranolol completely eliminated multiple auditory and visual trigger symptoms related to other people eating. His trigger response symptoms included overwhelming negative emotions and prominent sympathetic overactivity (fight-or-flight response). These symptoms were so severe that he had avoided most meals with friends and family for the past several years. Propranolol eliminated the emotional and physiological effects of both the auditory and visual triggers, with an Amsterdam Misophonia Scale score reduction from 15 to 2. This enabled him to resume eating meals with family and friends with no distress. The medication was well tolerated. In summary, we report the novel finding that β-blockers were markedly effective at treating the physical and emotional symptoms of a patient with misophonia and misokinesia. This suggests a novel treatment approach for these conditions.
@article{webb_-blockers_2022,
	title = {β-{Blockers} for the {Treatment} of {Misophonia} and {Misokinesia}.},
	volume = {45},
	copyright = {Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.},
	issn = {1537-162X 0362-5664},
	doi = {10.1097/WNF.0000000000000492},
	abstract = {Misophonia is an adverse physical and emotional reaction to certain repetitive trigger sounds, usually generated by other people. Misokinesia refers to visual  triggers that are sometimes (but not always) related to trigger sounds. Despite how  common and disabling these conditions can be, medication treatment of misophonia and  misokinesia is largely unexplored. We present the first case of using a β-blocker  (propranolol) to successfully treat a patient experiencing misophonia and  misokinesia. A moderate dose (60 mg) of propranolol completely eliminated multiple  auditory and visual trigger symptoms related to other people eating. His trigger  response symptoms included overwhelming negative emotions and prominent sympathetic  overactivity (fight-or-flight response). These symptoms were so severe that he had  avoided most meals with friends and family for the past several years. Propranolol  eliminated the emotional and physiological effects of both the auditory and visual  triggers, with an Amsterdam Misophonia Scale score reduction from 15 to 2. This  enabled him to resume eating meals with family and friends with no distress. The  medication was well tolerated. In summary, we report the novel finding that  β-blockers were markedly effective at treating the physical and emotional symptoms  of a patient with misophonia and misokinesia. This suggests a novel treatment  approach for these conditions.},
	language = {eng},
	number = {1},
	journal = {Clinical neuropharmacology},
	author = {Webb, Jadon},
	month = feb,
	year = {2022},
	pmid = {35029865},
	note = {Number: 1
Place: United States},
	keywords = {*Adrenergic beta-Antagonists/therapeutic use, *Hyperacusis/drug therapy, *Phobic Disorders/drug therapy, Humans, Male},
	pages = {13--14},
}

Downloads: 0